HIV multiantigen vaccine - Bavarian Nordic

Drug Profile

HIV multiantigen vaccine - Bavarian Nordic

Alternative Names: 2E8 TCID50 MVA-mBN120B - Bavarian Nordic; MVA-BN HIV multiantigen; MVA-HIV multiantigen vaccine MVA-mBN120B - Bavarian Nordic; MVA-mBN120B

Latest Information Update: 29 Sep 2015

Price : $50

At a glance

  • Originator Bavarian Nordic
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - HIV-1 infections

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 29 May 2008 Phase-I/II clinical trials in HIV-1 infections in USA (SC)
  • 29 Apr 2008 Preclinical trials in HIV-1 infections in USA (Parenteral)
  • 29 Apr 2008 Bavarian Nordic files an IND application with the USA FDA to begin a phase I/II trial for treatment of HIV-1 infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top